Strata Critical Medical (SRTA) Q2 2024 earnings summary

Executive summary

• Achieved first positive Adjusted EBITDA as a public company in Q2 2024, with both Medical and Passenger segments contributing positively; net loss improved to $(11.3) million.

• Total revenue rose 11.4% year-over-year to $67.9 million, with strong growth in both Medical and Passenger segments.

• Medical segment achieved record quarterly revenue of $38.3 million, up 11.5% year-over-year and 6.4% sequentially; Passenger segment posted its first positive Q2 Adjusted EBITDA.

• Flight profit increased 57.7% to $16.4 million, with flight margin up to 24.1% from 17.0% year-over-year.

• Liquidity remains strong with $142 million in cash and short-term investments and no debt as of June 30, 2024.

Financial highlights

• Q2 2024 revenue: $67.9 million, up 11.4% year-over-year; Medical segment revenue reached $38.3 million, up 11.5% year-over-year and 6.4% sequentially.

• Adjusted EBITDA was $1.0 million, a $5.4 million improvement from the prior year.

• Medical segment Adjusted EBITDA increased 82.7% to $5.5 million; Passenger segment Adjusted EBITDA improved to $0.8 million from a $2.1 million loss.

• Flight margin expanded to 24.1% from 17.0% year-over-year; gross margin rose to 16.7% from 8.3%.

• Net loss per share improved to $(0.15) from $(0.17) in Q2 2023.

Outlook and guidance

• Reaffirmed full-year 2024 guidance: revenue of $231–$250 million and positive Adjusted EBITDA.

• For 2025, expects double-digit year-over-year revenue growth and double-digit Adjusted EBITDA.

• Medical revenue and Adjusted EBITDA expected to be flat in Q3 before resuming low single-digit sequential growth; similar year-over-year growth expected in H2 2024.

• Passenger segment Adjusted EBITDA projected to improve year-over-year in Q3 and Q4.

• Adjusted Unallocated Corporate Expenses expected to be flat to down sequentially for the rest of the year.